Nodality Showcases Novel, Proprietary Technology to Predict Response to Therapy and Relapse Risk in Cancer Patients
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc., developing highly predictive tests to enable biologically informed clinical treatment decisions, today announced the presentation of promising data related to the application of the company's novel, proprietary technology, Single Cell Network Profiling (SCNP) in hematologic malignancies. SCNP measures the activation levels of ...
Read more on Business Wire
Orignal From: Nodality Showcases Novel, Proprietary Technology to Predict Response to Therapy and Relapse Risk in Cancer Patients
Post a Comment